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ABSTRACT
It is largely recognized that microRNAs (miRNAs)
function to silence gene expression by targeting
30UTR regions. However, miRNAs have also been
implicated to positively-regulate gene expression
by targeting promoter elements, a phenomenon
known as RNA activation (RNAa). In the present
study, we show that expression of mouse Cyclin
B1 (Ccnb1) is dependent on key factors involved
in miRNA biogenesis and function (i.e. Dicer,
Drosha, Ago1 and Ago2). In silico analysis
identifies highly-complementary sites for 21
miRNAs in the Ccnb1 promoter. Experimental
validation identified three miRNAs (miR-744,
miR-1186 and miR-466d-3p) that induce Ccnb1 ex-
pression in mouse cell lines. Conversely,
knockdown of endogenous miR-744 led to
decreased Ccnb1 levels. Chromatin immunopre-
cipitation (ChIP) analysis revealed that Ago1 was
selectively associated with the Ccnb1 promoter
and miR-744 increased enrichment of RNA poly-
merase II (RNAP II) and trimethylation of histone
3 at lysine 4 (H3K4me3) at the Ccnb1 transcription
start site. Functionally, short-term overexpression
of miR-744 and miR-1186 resulted in
enhanced cell proliferation, while prolonged
expression caused chromosomal instability and
in vivo tumor suppression. Such phenotypes
were recapitulated by overexpression of Ccnb1.
Our findings reveal an endogenous system by
which miRNA functions to activate Ccnb1 expres-
sion in mouse cells and manipulate in vivo tumor
development/growth.
INTRODUCTION
Small RNA including short interfering RNA (siRNA),
microRNA (miRNA) and Piwi-interacting RNA
(piRNA) have emerged as master regulators of gene ex-
pression and play important roles in diverse biological
processes and diseases (1). miRNAs are endogenous 20-
to 24-nt small RNAs transcribed from the genome as
primary miRNAs, which are processed into mature
miRNAs by ribonuclease (RNase) III family members
Drosha and Dicer (2). By interacting with members of
the Argonaute (Ago) subfamily of proteins (1), miRNAs
mainly target homologous sites in 30 untranslated regions
(UTRs) to suppress translation (3) and/or degrade mRNA
in a mechanism known as RNA interference (RNAi).
Cases in which miRNAs target 50-UTRs (4,5), coding
regions (6), promoters (7,8), or sequences downstream of
gene termini (9) to silence gene expression have also been
reported, raising the possibility of multiple modes of
action for miRNAs. Complexity of miRNA-mediated
gene regulation is further expanded by observations that
miRNAs can positively affect gene expression. For
example, miR-122 can enhance hepatitis C viral (HCV)
gene replication by targeting 50-non-coding elements in
the HCV genome (10,11). miR-369-3 has been shown to
activate mRNA translation by targeting AU-rich elements
in 30-UTRs under serum starvation (12,13). miR-10a has
also been shown to enhance translation by interacting
with the 50-UTR of ribosomal protein mRNAs (14).
The potential impact of small RNA species, especially
miRNAs, on gene transcription, epigenetic memory and
genome integrity is largely an under-explored territory.
Previously, we and others have shown that exogenous
dsRNAs targeting promoter sequences can either
suppress (15) or activate gene expression (16–20) by mech-
anisms respectively referred to as transcriptional gene
silencing (TGS) and RNA activation (RNAa).
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Sequencing and bioinformatics analyses have found that a
majority of miRNAs are imported back into the nucleus
after maturation (21) with an abundance of putative
miRNA target sites in gene promoters (7,22) to suggest
that miRNAs may also function in TGS and/or RNAa.
Indeed, miR-320—transcribed from the promoter of the
POLR3D gene—has been shown to suppress PLOR3D
transcription in cis (7), whereas miR-373 has been shown
to function in trans by activating the expression of
E-cadherin and cold shock domain-containing protein
C2 (CSDC2) through promoter sites (23). Recently,
Younger et al. (8) reported another trans-acting miRNA
(miR-423-5p) that functioned to suppress progesterone
receptor (PR) gene transcription by targeting an antisense
non-coding RNA overlapping the PR promoter. So far,
studies have not followed up on the endogenous functions
of these promoter-targeting miRNAs specifically in the
context of cancer.
Lines of evidence show that some miRNAs act as onco-
genes (24) or tumor suppressor genes (25) by modulating
molecular pathways involved in human cancer. It is rea-
sonable to speculate that endogenous miRNAs may be
involved in tumorigenesis via a nuclear function that
impacts gene transcription and epigenetic states. In the
present study, we show that the expression of mouse
Cyclin B1 (Ccnb1) is partially dependent on the miRNA
machinery (i.e. Drosha, Dicer, Ago1 and Ago2) in
immortal mouse cell lines. In silico analysis identifies
multiple miRNAs with putative sites complementary to
sequence in the Ccnb1 promoter. Subsequent experimen-
tation reveals that several miRNAs (e.g. miR-744 and
miR-1186) can induce Ccnb1 expression and enhance
cell proliferation; however, prolonged overexpression
causes chromosomal alterations and in vivo tumor sup-
pression. Our results reveal an endogenous function for
miRNA in gene activation and cancer cell growth.
MATERIALS AND METHODS
siRNA and synthetic miRNA
siRNAs against mouse Drosha, Dicer, Ago1, Ago2 and
Ccnb1 were designed using BLOCK-iTTM RNAi Designer
Program (Invitrogen). Synthetic miRNA mimics were
purchased from Qiagen (miScript miRNA mimics).
miRNA seed mutants and biotinylated miR-744 were
synthesized by Sigma. All siRNA and miRNA sequences
are listed in Supplementary Table S3.
Plasmids
Genomic sequences encompassing pre-miR-1186 and
pre-miR-744 were amplified from DNA isolated from
NIH/3T3 cells and cloned into the lentiviral expression
vector pPS-EF1-copGFP-LCS via the Clone-itTM
Ligase free system (System Biosciences) to generate the
miRNA overexpression constructs. Mouse Ccnb1 was
amplified from cDNA samples and cloned into the
lentiviral cDNA expression vector pCDH-EF1-
MCS-T2A-copGFP (System Biosciences) via the EcoRI
and BamHI sites to generate a Ccnb1 overexpression con-
struct. Vectors pIRESneo-FLAG/HA-Ago1 and
pIRESneo-FLAG/HA-Ago2 (Addgene plasmids 10 820
and 10 822) were used to establish Ago1 (NIH/
3T3-Ago1) and Ago2 (NIH/3T3-Ago2) stable cell lines,
respectively.
miRNA target prediction
miRNA targets on Ccnb1 promoter were predicted using
the miRanda program (26) run on a Linux operating
system. One kilobase of the mouse Ccnb1 promoter
sequence was retrieved from the Ensembl genome
database (www.ensembl.org), while mouse miRNA se-
quences were retrieved from miRBase (www.mirbase.
org). The Ccnb1 promoter sequence was scanned against
all known mouse miRNAs to identify putative target sites.
An alignment score of 140 was set as the positive predic-
tion threshold. The program’s output results were further
processed by a custom Perl script to sort target prediction
by alignment score and derive statistical information.
Cell culture and transfection
NIH/3T3 cells (ATCC) were maintained in high-glucose
(4.5 g/l) Dulbecco’s modified Eagle medium (UCSF Cell
Culture Core) supplemented with penicillin G (100U/ml),
streptomycin (100 mg/ml), 10% bovine calf serum
(Atlanta) in a humidified atmosphere of 5% CO2 main-
tained at 37C. TRAMP C1 (mouse prostate adenocarcin-
oma) cells were originally derived from the TRAMP
(transgenic adenocarcinoma mouse prostate) mouse
model and cultured as previously described (27). NIH/
3T3 or TRAMP C1 cells (1 104) were transfected
with synthetic siRNA or miRNA mimics by reverse trans-
fection using Lipofectamine RNAiMax (Invitrogen) ac-
cording to manufacturer’s protocol. NIH/3T3-eGFP,
NIH/3T3-Ago1 and NIH/3T3-Ago2 stable cell lines were
established by standard transfection, selection, and propa-
gation protocols. Briefly, single colonies were subcultured
following selection by G418. Ago1 and Ago2 expression
was confirmed by immunoblot analysis.
Lentivirus-based overexpression
Lentivirus particles were generated by transfecting 293FT
cells (Invitrogen) with lentivirus vector and packaging
plasmids according to the instructions provided with the
ViraPowerTM Lentiviral Expression System (Invitrogen).
NIH/3T3 and TRAMP C1 cells were infected twice with
the viral supernatant harvested at 48 and 72 h following
transfection and positively transduced (GFP positive) cells
were sorted by FACS (UCSF Laboratory of Cell
Analysis).
RNA extraction and real-time PCR analysis
Total RNA was isolated by using the RNeasy Mini Kit
(Qiagen) and reverse transcribed with MMLV reverse
transcriptase (Promega) in conjunction with oligo(dT)
primers. The resulting cDNA samples were subjected to
real-time PCR analysis using gene-specific primers (se-
quences are available in Supplementary Table S3). Small
RNA was extracted by using the miReasy Mini Kit
(Qiagen). Reverse transcription reactions were performed
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using the Taqman miRNA reverse transcription system
(Applied Biosystems). Expression levels of each miRNA
were detected by Taqman miRNA assays (Applied
Biosystems).
Immunoblotting
Cells were washed with PBS and lysed in RIPA buffer
(50mM Tris, pH 7.4, 150mM NaCl, 1% Triton X-100,
0.5% deoxycholate, 0.1% SDS, protease inhibitor cocktail
and phosphatase inhibitor) for 15min at 4C. Lysates
were clarified by centrifugation for 15min at 14 000 rpm
and supernatants were collected. Protein concentration in
the soluble fraction was determined by BCA protein assay
(Thermo Scientific). Equal amounts of protein were
resolved on SDS–PAGE gel and transferred to nitrocellu-
lose membrane. Blots were blocked overnight with 5%
nonfat dry milk in TBST. Specific proteins were detected
by using SuperSignal West Pico Chemiluminescent
reagents (Thermo Scientific). The following antibodies
were used at the indicated dilutions: anti-Ccnb1 V152
(Cell Signaling) at 1:1000, anti-HA 6E2 (Cell Signaling)
at 1:1000, anti-Histone H3 (Cell signaling) at 1:1000,
anti-Phospho-Histone H3 (Ser10) (Cell Signaling) at
1:500, anti-Tubulin (Sigma) at 1:1000 and
anti-Topoisomerase I (Santa Cruz) at 1:500. Anti-b-actin
(Sigma) at 1:3000 was used as a loading control.
Subcellular fractionation
Cytoplasmic and nuclear fractions were prepared by using
the NE-PER Nuclear and Cytoplasmic Extraction
Reagents (Thermo Scientific). Immunodetection of
b-tubulin and Topoisomerase I were used as cytoplasmic
and nuclear markers, respectively.
Chromatin immunoprecipitation
NIH/3T3-Ago1, NIH/3T3-Ago2, or NIH/3T3-eGFP cells
were cultured to 70-80% confluency in 10-cm plates.
Cells were fixed with 1% formaldehyde in serum-free
media for 10min at room temperature. Formaldehyde
crosslinking was quenched with 125 mM glycine (final con-
centration). Cells were washed in PBS and nuclei were
prepared as previously described (28). Cell suspension
was sonicated 12 times in 10-s pulses to yield DNA frag-
ments with an average length of 500 bp. Lysates were
pre-cleared with Protein A/G sepharose beads (GE
Healthcare) and subsequently incubated with or without
5 ml of anti-HA antibody (Cell Signaling) at 4C overnight.
Samples omitting antibody were used as negative controls.
Fresh beads were then added for 2 h to immunoprecipitate
chromatin and sequentially washed in low salt, high salt,
LiCl and TE buffer. DNA/protein complexes were eluted
and crosslinking was reversed by heating overnight at
65C. Samples were subsequently treated with Proteinase
K followed by phenol/chloroform extraction and RNase
A treatment. DNA fragments were then purified in
nuclease free water using Qiaquick PCR purification
columns (Qiagen). For RNAP II and H3K4me3 ChIP ex-
periments, NIH/3T3 cells were transfected at 100 nM
dsControl or miR-744 for 3 days, while TRAMP-C1-
miR-EV and TRAMP-C1-miR-744 cells were cultured to
70–80% confluency in 10 cm plates prior to harvest.
Antibodies to RNAP II and H3K4me3 were purchased
from Millipore. For ChIP–immunoblot analysis, NIH/
3T3-Ago1 cells were transfected with 100 nM
biotin-labeled miR-744 or dsControl for 3 days.
Immunoprecipitation was performed with Dynabeads
M-280 Streptavidin (invitrogen) followed by immunoblot-
ting with an anti-HA antibody.
ChIP and quantitative PCR analysis (ChIP–qPCR)
Primers covering the 2-kb promoter region of mouse
Ccnb1 were designed using Primer Express v2.0 (Applied
Biosystems). Each PCR reaction was performed in tripli-
cate in 10 ml reaction volumes containing 2 ml of ChIP–
enriched or input DNA, Power SYBR Green master mix
(Applied Biosystems), and region specific primer
sets. Target amplification and detection was per-
formed by the ABI Prism 7500 Real-Time System.
Fold enrichment=2(delta CTexpt –
delta CT
control
) where
delta CT=CTIP –CTno antibody control, expt=Ccnb1
promoter, control=negative control region. Specificity
of the PCR reactions was confirmed by electrophoresis
and dissociation curve analysis. Primer sequences are
listed in Supplementary Table S3.
Propidium iodide staining and cell cycle analysis
Cells were trypsinized and centrifuged at 1000 rpm for
5min at 4C. Cell pellets were resuspended in 500 ml cold
saline GM solution (6.1mM glucose, 1.5mM NaCl,
5.4mM KCl, 1.5mM Na2HPO4, 0.9mM KH2PO4,
0.5mM EDTA). The resuspended cells were fixed in
1.5ml cold 100% ethanol for at least 2 h at 4C. Cells
were washed twice with cold PBS and resuspended in
1ml propidium iodide staining solution (50 mg/ml
propidium iodide, 10mg/ml RNase A, 0.1% Triton
X-100, 0.1% sodium citrate in PBS) and incubated at
room temperature for 30min. The stained cells were im-
mediately analyzed on a FACSCaliber flow cytometer
(UCSF Laboratory of Cell Analysis) for relative DNA
content. Collected data was evaluated using ModFit
software (Verity Software House, Topsham ME).
Cell proliferation and doubling time analysis
TRAMP C1 cells (1 104) expressing empty vector,
miR-744, miR-1186, or Ccnb1 cDNA were seeded in
six-well plates. The cells were trypsinized and viable cells
were counted on Days 1–5. Doubling time was calculated
from four independent experiments using an online
doubling time calculator (http://www.doubling-time.com/
compute.php). For the growth rescue experiment,
TRAMP-C1-miR-EV and TRAMP-C1-miR-744 cells
were transfected with 50 nM dsControl or siCcnb1 in a
96-well format. Cell proliferation was measured by using
the CellTiter96 Aqueous One Solution cell proliferation
assay kit (Promega) according to manufacturer’s protocol.
Karyotyping
Parental or TRAMP C1 sublines were treated with 10 ng/
ml Colcemid (Invitrogen) in culture medium overnight at
Nucleic Acids Research, 2012, Vol. 40, No. 4 1697
37C. Cells were harvested and G-banded according to the
standard mouse karyotyping protocol (28). The G-banded
chromosomes were analyzed using CytoVision system
(Applied Imaging) and karyotyped according to the
standard mouse chromosome nomenclature (29,30).
Xenograft model
TRAMP C1 stable cell lines were grown to 80%
confluency in 15-cm dishes, trypsinized, and counted.
Cells (2 106) in 200 ml PBS containing 50% matrigel
were injected into the right lower flank of 4-week-old
male athymic (nu/nu) mice (Simonsen Laboratories).
The mice were monitored for tumor volume, body
weight, and overall health for 35 days. Digital calipers
were used to monitor tumor size and volume utilizing
the formula (widthwidth length)/2. Each experimen-
tal and control group contained six mice. At the end of the
animal study, all mice were sacrificed according to
protocol approved by the Institutional Animal Care and
Use Committee (IACUC). Body and tumor weight were
recorded following tumor resection.
Statistical analysis
Data was analyzed using the StatView program (SAS
Institute Inc., Cary, NC). The 2 test was used to assess
the significance of the differences between proportions.
The difference in continuous variables between treatments
was assessed by Student’s t-test or ANOVA. In all cases,
P-values< 0.05 were considered statistically significant.
RESULTS
Ccnb1 expression depends on components of the miRNA
pathway
Canonical biogenesis of functionally mature miRNA is
dependent, in part, on ribonuclease III family members
Drosha and Dicer (2). It is anticipated that the expression
of genes positively-regulated by endogenous miRNAs may
be sensitive to perturbation in miRNA maturation. In
support, RNAa facilitated by pre-miRNA has been
shown to be dependent on Dicer for gene activation
(23). To identify putative examples of endogenous
miRNA-mediated gene activation, we depleted Drosha
or Dicer by RNAi in NIH/3T3 (mouse embryonic fibro-
blast) cells and screened for transcripts cooperatively
depleted with Drosha or Dicer by real-time PCR (data
not shown). Surprisingly, depletion of the miRNA biogen-
esis components downregulated a large number of cell
cycle genes, including Cyclin B1 (Ccnb1), implying that
miRNAs may positively regulate cell-cycle genes. As
shown in Figure 1A and B, knockdown of Drosha and
Dicer depleted Ccnb1 mRNA expression by 20% and
35%, respectively.
The function of miRNAs largely depends on the Ago
subfamily of proteins (Ago1 through Ago4), which
function as components of the miRNA effector
ribonucleoprotein (miRNP). Ago1 and Ago2 have been
shown to mediate dsRNA-guided transcriptional gene
silencing (31,32) and activation (33,34) suggesting a uni-
versal role for Ago proteins in most, if not all, mechanisms
of small RNA-guided gene regulation. To examine
whether Ago1 and Ago2 are also required in
miRNA-mediated Ccnb1 gene activation, we transiently
knocked down Ago1 or Ago2 in NIH/3T3 cells by
siRNA (siAgo1 or siAgo2) and examined Ccnb1 expres-
sion. siAgo1 resulted in >70% knockdown of Ago1 and
caused a corresponding 70% reduction in Ccnb1 mRNA
level as detected at 72 h following siAgo1 transfection
(Figure 1C). Despite the low efficiency of Ago2
knockdown, siAgo2 also caused a subtle reduction
(20%) in Ccnb1 mRNA levels (Figure 1D).
Conversely, we established stable lines from NIH/3T3
cells that expressed HA-tagged human Ago1 or Ago2
(NIH/3T3-Ago1 or NIH/3T3-Ago2) (Figure 1E) and
examined Ccnb1 expression. As shown in Figure 1F,
Ccnb1 mRNA was increased by 1.7-fold in NIH/
3T3-Ago1 cells as compared to the control NIH/3T3 cell
line expressing only enhanced GFP (NIH/3T3-eGFP).
Ccnb1 mRNA was also moderately induced (1.3-fold)
by Ago2 overexpression (Figure 1F). Taken together,
these results indicate that key components of miRNA bio-
genesis and the miRNP effector complex positively
regulate Ccnb1 expression.
miRNA-mediated activation of Ccnb1 expression
To identify candidate miRNA(s) that may be involved in
positively regulating Ccnb1 expression, we used the
miRanda algorithm (35) to scan 1-kb of Ccnb1
promoter sequence for potential target sites complemen-
tary to known mouse miRNAs included in the miRBASE
database (www.mirbase.org). By setting the prediction
stringency level to medium-high, in silico analysis
identified a total of 22 putative targets for 21 miRNAs
on the Ccnb1 promoter (Supplementary Table S1). The
top four miRNAs with the highest alignment scores
including miR-1186, miR-744, miR-1196 and miR-1962
were selected for further validation. These miRNAs have
significant sequence homology with the Ccnb1 promoter
both in their ‘seed’ (nucleotide 2–8) and extended regions
(Supplementary Table S1), but do not possess putative
target sites in either the 30- or 50-UTR of the Ccnb1 tran-
script. We transfected synthetic miRNA mimics of the
four candidate miRNAs or a control miRNA
(dsControl) into NIH/3T3 cells and assessed Ccnb1 ex-
pression levels five days later. Compared to control treat-
ments, miR-744 and miR-1186 caused a 2.6- and 2-fold
induction in Ccnb1 mRNA levels, respectively (Figure 2A
and B). However, transfection of miR-1196 or miR-1962
had little-to-no effect on Ccnb1 transcript levels
(Supplementary Figure S1A and B). At Day 5, cellular
levels of miR-744 and miR-1186 were increased
>300-fold following transfection of their respective
mimics compared to controls (Supplementary Figure
S2A and B). The induction of Ccnb1 by miR-744 and
miR-1186 was further confirmed by immunoblot analysis
in NIH/3T3 cells (Figure 2C). Sequence requirement was
investigated by mutating the ‘‘seed’’ region of both
miR-744 and miR-1186. The mutation in both miRNAs
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(miR-744-MM and miR-1186-MM) abolished their ability
to activate Ccnb1 expression (Supplementary Table S3,
Supplementary Figure S3A and B). In contrast, a
miR-744 variant (miR-744-Perfect) with improved com-
plementary to the predicted miR-744 target site did not
suffer from reduced activity; rather, it retained function
and readily activated Ccnb1 expression in a manner
similar to miR-744 (Supplementary Figure S3A and C).
miR-744 and miR-1186 were selected for subsequent
studies given that both miRNAs induced Ccnb1 expres-
sion. miR-744 potentially targets position 192 in the
Ccnb1 promoter relative to the transcription start site
(TSS) with an overall sequence identity of 93%
(Figure 2A and Supplementary Table S1). This site, in
particular the sequence complementary to the ‘seed’
region, is also conserved among seven mammalian
species (Supplementary Figure S4). miR-1186 targets a
repetitive region on the Ccnb1 promoter at position
699 with a 94% sequence identity (Figure 2A and
Supplementary Table S1). We further transfected
miR-744 and miR-1186 mimics into the TRAMP C1
cells and observed a 1.3- and 1.6-fold induction in
Ccnb1 mRNA levels, respectively (Figure 2D).
Immunoblot analysis confirmed that Ccnb1 protein
expression was also induced by both miRNAs in
TRAMP C1 cells (Figure 2E).
To determine if constitutive expression of miRNA
could also induce Ccnb1 expression, we stably expressed
precursor miR-744 (Lenti-miR-744) and miR-1186
(Lenti-miR-1186) in TRAMP C1 cells via lentiviral-
mediated transduction. Lenti-miR-744 and Lenti-miR-
1186 caused a respective increase in the levels of mature
miR-744 and miR-1186 by 10- and 1.5-fold as
compared to the empty vector control (Lenti-miR-EV)
(Supplementary Figure S5A and B). As shown in
Figure 2F, Ccnb1 protein levels were induced in both
miR-744 and miR-1186 stable expressing cell lines suggest-
ing naturally-processed miRNAs also induce Ccnb1.
To verify if downregulation of Ccnb1 also correlated
with depletion of miRNA levels following perturbation
of Dicer or Drosha, we evaluated endogenous miR-744
levels and found a 30–60% reduction in mature miR-744
following siDicer and siDrosha treatments, respectively
(Supplementary Figure S6A). Ago proteins have been
shown to stabilize mature miRNAs leading to an
increase in their abundance (36). Indeed, overexpression
of either Ago1 or Ago2 caused a subtle increase in the
levels of mature miR-744 (Supplementary Figure S6B)
Figure 1. Ccnb1 expression depends on components of the miRNA pathway. (A–D) NIH/3T3 cells were transfected at 50 nM with the indicated
siRNAs for 72 h. dsControl served as non-specific control duplex. Mock samples were transfected in the absence of siRNA. Relative expression levels
were quantified by real-time PCR using gene-specific primer sets. Values were normalized to b-actin. (E) Establishment of NIH/3T3-Ago1 and NIH/
3T3-Ago2 cell lines. Expression of HA-tagged Ago1 and Ago2 was confirmed by immunoblot analysis using an antibody specific to the HA epitope
(anti-HA). NIH/3T3-eGFP cells served as a control cell line. (F) Expression levels of Ccnb1 were determined by real-time PCR in NIH/3T3-Ago1
and NIH/3T3-Ago2 cell lines relative to NIH/3T3-eGFP cells. Values were normalized to b-actin. All data represents mean±SE of three inde-
pendent experiments; *P< 0.05.
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suggesting Ccnb1 induction upon Ago1 or Ago2
overexpression may result, in part, from a stabilization
of miR-744. Knockdown of Ago1 or Ago2 did not cause
any significant reduction in the steady-state levels of
mature miR-744 (Supplementary Figure S6A). As such,
declines in Ccnb1 following siAgo1 and siAgo2 treatments
occurred regardless of miR-744 levels suggesting Ago
proteins may function as mediators of miRNA-guided
Ccnb1 transcription.
To further demonstrate a correlation between miR-744
depletion and Ccnb1 downregulation, we used a pool of
two siRNAs (si-miR-744) to knockdown endogenous
miR-744 expression. The siRNAs were designed to
target the pre-miR-744 loop sequence, which decreased
miR-744 levels by 40% compared to control siRNA
(dsControl) treatments in NIH/3T3 cells (Figure 2G).
Concurrently, si-miR-744 also decreased Ccnb1 mRNA
expression by 32% (Figure 2G).
Although knockdown of miR-744 correlated with
Ccnb1 downregulation, other miRNAs (i.e. miR-1186)
may also function to positively-regulate Ccnb1 expression.
To determine if other miRNAs from the target predication
list (Supplementary Table S1) also influenced Ccnb1 ex-
pression, we transfected NIH/3T3 cells with miR-466d-3p.
Although miR-466 d-3p is ranked 19th on the list by align-
ment score, it possesses a higher sequence complementar-
ity within its ‘seed’ and extended regions to its putative
target site in the Ccnb1 promoter compared to other
higher ranking miRNAs (Supplementary Table S1).
Transfection of miR-466d-3p caused 1.5-fold increase
in Ccnb1 mRNA and protein expression (Supplementary
Figure S1A, C and D). Taken together, these findings
indicate that Ccnb1 transcription may be
positively-regulated by multiple miRNAs, which may
have physiological context in disease and miRNA
dysregulation.
Ago1 is associated with Ccnb1 promoter
Since Ccnb1 expression depends on Ago1 and Ago2, we
reasoned that they may be recruited to the Ccnb1
promoter. To test this view, we performed scanning
ChIP to examine the association of Ago1 and/or Ago2
Figure 2. miRNAs targeting the Ccnb1 promoter induce Ccnb1 expression. (A) Schematic representation of the Ccnb1 promoter and miRNA target
locations relative to the TSS. (B and D) NIH/3T3 or TRAMP C1 cells were transfected with 100 nM miRNA control (dsControl), miR-744, or
miR-1186 for 5 days. Mock samples were transfected in the absence of miRNA. Ccnb1 mRNA levels were analyzed by real-time RT–PCR and
normalized to b-actin levels. (C and E) NIH/3T3 or TRAMP C1 cells were transfected as in (B and D). Proteins levels of Ccnb1 and b-actin were
evaluated by immunoblot analysis. Detection of b-actin served as a loading control. (F) Ccnb1 and b-actin protein levels were determined by
immunoblot analysis in stable TRAMP C1 cells infected with either lenti-miR-744 or lenti-miR-1186 virus particles. Cells stably expressing the empty
vector (Lenti-miR-EV) were established as a control. (G) NIH/3T3 cells were transfected with 100 nM dsControl or si-miR-744 for 72 h. miR-744
levels were evaluated by real-time RT–PCR and standardized to U6 levels, while Ccnb1 expression was normalized to b-actin. All data represents
mean±SE of three independent experiments; *P< 0.05, **P< 0.005.
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at the mouse Ccnb1 promoter in stable NIH/3T3 cell lines
overexpressing HA-tagged Ago1 (NIH/3T3-Ago1) or
Ago2 (NIH/3T3-Ago2) by using an HA-specific
antibody. Stable NIH/3T3 cells expressing HA-tagged
eGFP (NIH/3T3-eGFP) were used as a negative control.
Six primer pairs encompassing select regions (Region
A–F) across 2-kb of the mouse Ccnb1 promoter were
designed to amplify DNA pulled down by the
HA-tagged Ago proteins (Figure 3A). We quantitatively
determined enrichment of HA-Ago1 and HA-Ago2 at the
selected regions by real-time PCR. All data was
normalized to an intergenic control (Control) region
anticipated to have no Ago protein association. A
3-fold enrichment of HA-Ago1 was detected in Region
E (285/228) of the Ccnb1 promoter, which was just
proximal to the putative miR-744-binding site (192/
171) (Figure 3B). No significant HA-Ago2 enrich-
ment was detected in the scanned promoter regions in
NIH/3T3-Ago2 cells (Figure 3B). Subcellular fraction-
ation experiments also revealed that both HA-tagged
Ago1 and Ago2 localize to the nuclear and cytosolic frac-
tions in the NIH/3T3 sublines (Figure 3C). Furthermore,
ChIP–immunoblot analyses in NIH/3T3-Ago1 cells trans-
fected with biotin-labeled miR-744 revealed HA-Ago1 was
present in the streptavidin pulldown indicating that
miR-744 is bound to Ago1 (Figure 3D). This data
indicates HA-Ago1 is enriched at the Ccnb1 promoter,
found in the nucleus, and can associate with exogenous
miR-744.
Upregulation of Ccnb1 by miR-744 correlates with
increased RNAP II occupancy and H3K4me3
at Ccnb1 promoter
Transcription activation is associated with RNA polymer-
ase II (RNAP II) enrichment and epigenetic modulation
such as histone H3 lysine 4 tri-methylation (H3K4me3) at
Figure 3. Ago1 associates with the proximal promoter of mouse Ccnb1. (A) Schematic illustration of the primer amplicons (Regions A–F) used for
scanning ChIP analysis of 2 kb of the proximal Ccnb1 promoter. Locations are shown relative to the TSS. (B) ChIP experiments were performed with
an anti-HA antibody in NIH/3T3-Ago1, NIH/3T3-Ago2 and NIH/3T3-eGFP cells to examine Ago1/2 enrichment within the Ccnb1 promoter.
Real-time PCR was utilized to quantify fold enrichment of Ago1 and/or Ago2 at designated primer regions relative to no antibody controls. Data
was normalized to an intergenic region (Control) devoid of Ago binding. (C) Subcellular localization of Ago1 and Ago2. Whole-cell lysate (WCL),
nuclear (N) and cytoplasmic (C) extracts were analyzed by immunoblot analysis in NIH/3T3-Ago1 and NIH/3T3-Ago2 cell lines. HA-tagged Ago1
and Ago2 were detected using an anti-HA antibody. Topoisomerase I (Topo I) and b-tubulin served as nuclear and cytoplasmic markers, respect-
ively. (D) Biotinylated miR-744 associates with Ago1. NIH/3T3-Ago1 cells were transfected with biotinylated dsControl or miR-744 at 100 nM for 3
days. Immunoprecipitation (IP) was performed with streptavidin Dynabeads followed by immunoblotting (IB) with an anti-HA antibody to detect
HA-tagged Ago1. FT: flowthrough, Input: 10% input chromatin. (E and F) Enrichment of RNAP II and H3K4me3 at the Ccnb1 promoter. NIH/
3T3 cells were transfected with 100 nM dsControl or miR-744 for 72 h. ChIP–qPCR was utilized to quantify enrichment of RNAP II and H3K4me3
at the Ccnb1 TSS (Region F). Fold changes are relative to dsControl treatments and normalized to amplification values in IgG control samples.
(G) ChIP–qPCR analysis of H3K4me3 at the Ccnb1 TSS in TRAMP C1 sublines expressing either lenti-miR-EV or lenti-miR-744. Relative
enrichment was calculated as in (E and F). Error bars represent mean±SE of two independent experiments; *P< 0.05.
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gene promoters (19,23,37). To determine if miR-744 facili-
tates such changes at the Ccnb1 promoter, we performed
ChIP assays using antibodies specific to RNAP II and
H3K4me3. Following miR-744 transfection, 1.4-fold
increase in RNAP II occupancy was observed at the
Ccnb1 TSS compared to dsControl (Figure 3E).
H3K4me3 levels were also increased at the Ccnb1 TSS
in miR-744 transfected NIH/3T3 cells and Lenti-miR-
744 stable TRAMP C1 cells (Figure 3F and G). Taken
together, these results suggest that miR-744-induced
Ccnb1 expression involves RNAP II enrichment and epi-
genetic changes associated with active transcription. In
support, nuclear run-on experiments show direct tran-
scriptional upregulation of Ccnb1 in Lenti-miR-744
stable TRAMP C1 cells as compared to controls
(Supplementary Figure S7).
We also generated two artificial reporter systems in
which 3.2 kb of the Ccnb1 promoter was cloned
upstream of either GFP or luciferase to further investigate
the specificity of Ccnb1 activation. The Ccnb1
promoter-GFP chimera was stably integrated into NIH/
3T3 cells, while the luciferase construct was transiently
transfected with miRNA. As shown in Supplementary
Figure S8, neither miR-744 nor miR-1186 significantly
increased the activity of either exogenous reporter
system suggesting additional elements other than simple
sequence complementarity are required for gene
induction.
miR-744 and miR-1186 overexpression enhance cell
proliferation
Phenotypically, transfection of miR-744 and miR-1186
mimics into NIH/3T3 and TRAMP C1 cells induced
histone H3 phosphorylation at serine 10 (p-H3S10), a
marker for cell proliferation that correlates with chromo-
some condensation during mitosis (Figure 4A and B).
Cyclin B1 in complex with Cdk2 controls the G2-M tran-
sition of the cell cycle and is frequently overexpressed in a
variety of cancer cells to promote proliferation (38,39). To
determine if Ccnb1 overexpression recapitulates miR-744
and/or miR-1186 results, we established stable sublines
from NIH/3T3 and TRAMP C1 cells by utilizing a
lentiviral system to overexpress mouse Cyclin B1
(Lenti-Ccnb1). These sublines also exhibited elevated
p-H3S10 levels as compared to control cells expressing
an empty vector (Lenti-EV) (Figure 4C and D).
Phenotypically, TRAMP C1 cells infected with
Lenti-Ccnb1 (TRAMP-C1-Ccnb1), Lenti-miR744
(TRAMP-C1-miR-744), or Lenti-miR1186 (TRAMP-C1-
miR-1186) exhibited a shorter doubling time compared to
the TRAMP C1 parental line or cells expressing an empty
vector control (TRAMP-C1-miR-EV) (Figure 4E).
To further confirm that Ccnb1 activation is responsible
for enhanced cell proliferation by miR-744, we performed
a rescue experiment by utilizing RNAi to knockdown
Ccnb1 in TRAMP-C1-miR-744 cells. Compared to
dsControl treatments, Ccnb1 siRNA (siCcnb1) effectively
depleted Cyclin B1 levels in both TRAMP-C1-miR-EV
and TRAMP-C1-miR-744 cells (Supplementary
Figure S9). However, knockdown of Ccnb1 in
TRAMP-C1-miR-744 cells blocked the enhanced prolif-
erative effects associated with miR-774 overexpression
(Figure 4F). These findings suggest that miR-744 and
miR-1186 have a proliferative function that is, in part,
dependent on activation of Ccnb1.
miR-744 and miR-1186 induce cytogenetic changes in
TRAMP C1 cells
It has also been reported that overexpression of Ccnb1 can
result in chromosome instability (CIN) (40). To determine
if prolonged expression of Ccnb1, miR-744 and/or
miR-1186 affects the cytogenetic profile in mouse
prostate cancer cells in a manner similar to Ccnb1, we
performed karyotype analysis in TRAMP-C1-miR-744,
TRAMP-C1-miR-1186 and TRAMP-C1-Ccnb1 cells.
Twenty metaphase spreads from each cell line, as well as
the parental TRAMP C1 cell line, were subjected to cyto-
genetic characterization by G-banding.
As previously reported (41), TRAMP C1 cells were
highly aneuploid (Figure 5A and B) composed of two
major karyotypically discrete cell populations with
multiple marker chromosomes of unknown origin
(Supplementary Table S2). No cells possessed normal
karyotypes; rather, a majority of the cells (75%) contained
a chromosome number in the range of 91–130, while 25%
contained 51–90 chromosomes (Supplementary Table S2
and Figure 5B). Consistent with this finding, analysis of
DNA content by flow cytometry in cells stained with PI
revealed that TRAMP C1 cells contained two major
cycling populations with differential DNA content
referred to as the low and high distributions
(Supplementary Figure S10, top panel). Forward versus
side scatter plots showed that TRAMP C1 cells possessed
one phenotypically homogenous population excluding the
possibility of a mixture of two different cell types
(Supplementary Figure S10, bottom panel).
To closely compare the cytogenetic differences between
the cell lines, we calculated the percentage of analyzed
cells with chromosome numbers >90 or <90
(Figure 5A). Compared to empty vector control cells
(TRAMP-C1-miR-EV), miR-744 overexpressing cells
(TRAMP-C1-miR-744) exhibited a progressive loss of
chromosomes with increased passages. As shown in
Figure 5A–C and Supplementary Table S2, 45% of
TRAMP-C1-miR-EV cells (either low or high passage)
contained chromosome numbers between 51 and 90,
while 65% of the early passage (TRAMP-C1-miR-744
low, passage <10) and 75% of the late passage miR-744
overexpressing cells (TRAMP-C1-miR-744 high, pas-
sage> 30) (P< 0.05) contained chromosome numbers
<90. Furthermore, overexpression of miR-744 signifi-
cantly increased the number of marker chromosomes
(rearranged chromosomes that lost identities of origins)
(P< 0.03) (Supplementary Table S2). Late passage
miR-1186 overexpressing cells (TRAMP-C1-miR-1186
high, passage >30) also showed a reduction in total
chromosome number where only 10% of the analyzed
cells contained more than 110 chromosomes and 10%
contained chromosome numbers in the lowest range
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Figure 4. miR-744 and miR-1186 promote phosphorylation of histone H3 and enhance in vitro cell proliferation. (A and B) NIH/3T3 and TRAMP
C1 cells were transfected with 100 nM dsControl, miR-744 or miR-1186 for 5 days. Mock samples were transfected in the absence of miRNA. Total
H3 and phosphorylated H3S10 (p-H3S10) levels were examined by immunoblot analysis using specific antibodies. (C and D) Total H3 and p-H3S10
levels were immunodetected in stable NIH/3T3 and TRAMP C1 sublines infected with either lenti-Ccnb1 or lenti-EV viral particles. (E) The doubling
time of TRAMP C1 cells expressing empty vector (TRAMP-C1-miR-EV), miR-744 (TRAMP-C1-miR-744), miR-1186 (TRAMP-C1-miR-1186), or
Ccnb1 (TRAMP-C1-Ccnb1) was evaluated over the course of 5 days. The average doubling time (hrs)±SE of independent experiments is plotted in
the corresponding bar graph; *P< 0.05, **P< 0.01, NS: not significant compared to the TRAMP C1 parental cell line. (F) TRAMP-C1-miR-EV or
TRAMP-C1-miR-744 cells were transfected with 50 nM dsControl or siCcnb1. Cell proliferation was quantified at each day utilizing the CellTiter96
Aqueous One Solution. Error bars represents SE from four independent transfections. Statistical significance was determined between dsControl and
siCcnb1 treatments within each subline; *P< 0.05, **P< 0.01.
Figure 5. miR-744, miR-1186 and Ccnb1 induce conserved cytogenetic changes in TRAMP C1 cells. (A) Twenty randomly selected cells from the
parental TRAMP C1 or indicated derived sublines were subjected to G-banded karyotyping. Percent cell population (% cells) with chromosome
numbers >90 or <90 are indicated in the bar graph; *P< 0.05, **P< 0.001. (B–E) Representative chromosome spreads from parental TRAMP C1
(B), TRAMP-C1-miR-744 high (C), TRAMP-C1-miR-1186 high (D), or TRAMP-C1-Ccnb1 high (E) cells. Denoted in parentheses is the total
number of chromosomes found in corresponding spread.
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(chromosome number=31–50) (Supplementary Table S2
and Figure 5D). Similarly, analysis of DNA content by
flow cytometry revealed that overexpression of either
miR-744 or miR-1186 promoted a shift from a population
with high DNA content to low DNA content
(Supplementary Figure S10, top panel).
Analysis of TRAMP-C1-Ccnb1 cells also revealed a
similar pattern of cytogenetic changes in a passage-
dependent manner (Figure 5A and E). Compared to
empty vector control (TRAMP-C1-lenti-EV) where 35%
of the cells contained chromosome numbers <90, 45% of
the early passage (TRAMP-C1-Ccnb1 low, passage <5)
and 75% of the late passage Ccnb1 overexpressing cells
(TRAMP-C1-Ccnb1 high, passage >10) contained 51–90
chromosomes (Figure 5A and Supplementary Table S2)
(P < 0.001). It is noteworthy that TRAMP-C1-Ccnb1
cells required fewer passages to reach a similar degree of
CIN found in high passage miR-744 overexpressing cells
suggesting that high levels of Ccnb1 accelerate genomic
instability (Supplementary Table S2). Taken together,
these results suggest that prolonged expression of
miR-744 and miR-1186 induced cytogenetic changes in
TRAMP C1 cells in a manner similar to Ccnb1
overexpression.
Prolonged overexpression of miR-744 and miR-1186
inhibits tumorigenesis in vivo
Given that overexpression of Ccnb1 plays a role in
tumorigenesis (42,43), we decided to evaluate the tumori-
genicity of miR-744 and miR-1186 in a mouse subcutane-
ous xenograft model. Previous studies showed that
TRAMP C1 cells form tumors readily in vivo (27).
Indeed, six out of six mice inoculated with
TRAMP-C1-miR-EV control cells developed tumors
within 2 weeks. Comparatively, mice injected with early
passage miR-744 overexpressing cells (TRAMP-C1-
miR744 low, passage number <10) formed tumors with
an average size larger than the control group by the end of
the study (P=0.06) (Figure 6A) and appeared to be more
aggressive (tumors from two mice invaded the spinal
column) (Figure 6B). Strikingly, mice injected with late
passage miR-744 overexpressing cells (TRAMP-C1-
miR744 high, passage number >30) did not give rise to
any tumors at the injection site (Figure 6A and B). Late
passage miR-1186 overexpressing cells (TRAMP-C1-
miR1186 high, passage number >30) also formed signifi-
cantly smaller tumors than the control group (P< 0.005)
(Figure 6A and B). Collectively, our data suggests that
short-term expression of miR-744 and/or miR-1186 may
promote in vivo tumor growth through Ccnb1 activation;
however, prolonged activation of Ccnb1 may cause
chromosomal instability in TRAMP C1 cells and inhibit
tumor development/growth. In support, high levels of
genetic instability have been reported to have a tumor
suppressive effect in certain context (44,45).
DISCUSSION
In the present work, we demonstrate that the expression of
Ccnb1 depends on components of miRNA biogenesis
(Drosha and Dicer) and function (Ago1 and Ago2) in
mouse cells. We identify several miRNAs (e.g. miR-744,
miR-1186, etc.) with predicted target sites in the Ccnb1
promoter that induce Ccnb1 expression. Mechanistically,
we indicate that Ago1 and Ago2 are abundant in the
nucleus consistent with previous observations (46). Ago1
is localized to the proximal promoter region of Ccnb1 and
miR-744 promotes RNAP II and H3K4me3 enrichment at
the Ccnb1 TSS. Phenotypically, Ccnb1 overexpression has
been reported to promote tumorigenesis and function as a
putative oncogene in a variety of cancers (42,43,47–49). As
such, short-term overexpression of miR-744 or miR-1186
led to enhanced tumor cell proliferation in a manner
similar to vector-mediated overexpression of Ccnb1.
However, long-term expression in TRAMP C1 mouse
cells altered chromosome composition suggesting
Figure 6. Prolonged overexpression of miR-744 or miR-1186 alters in vivo tumor growth. (A) Cells (2 106) from the indicated stable TRAMP C1
sublines were injected into the right lower flank of male athymic mice and monitored for 35 days. Subcutaneous tumor dimensions were recorded
using calipers at the indicated time points (days) following initial inoculation. Tumor volume was calculated according to the formula
(widthwidth length)/2. Data is plotted as the mean volume±SE; *P< 0.05; **P< 0.01; ***P< 0.001. (B) Photographs of inoculated mice
and corresponding resected tumors from each group at time of sacrifice on Day 35.
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prolonged Ccnb1 activation may cause chromosomal in-
stability. Xenografts derived from early passage cells
overexpressing miR-744 also possessed enhanced tumori-
genicity, while cells from late passage populations dis-
played poor tumor growth in vivo. Our data suggests
that short-term expression of miR-744 and/or miR-1186
may promote in vivo tumor growth through Ccnb1 acti-
vation; however, prolonged activation of Ccnb1 may
cause chromosomal instability and inhibit tumor growth.
This study reveals a physiologically relevant role for
miRNA-mediated gene activation, which may be
implicated in cancer initiation and/or development.
miRNAs are known to participate in a wide variety of
cellular functions by suppressing gene expression via
binding complementary sites in the 30-UTR of mRNA se-
quences. Target predication in gene transcripts is largely
dependent on sequence complementarity within the ‘seed’
region and target conservation across multiple species
(50,51). However, without experimental validation, such
computational predictions are not always bona fide targets
(50). Predicting miRNA target sites in gene promoters is
even more challenging due to a lack of relevant experimen-
tal data and general poor conservation of promoters
across different species. However, by repurposing target
prediction algorithms (e.g. miRanda) to scan promoter
sequence for sites complementary to miRNAs, numerous
putative targets can be identified with reasonably high
score (22,52). As such, it has been postulated that
miRNAs may also play a regulatory role in fine-tuning
gene transcription in the nucleus (52,53).
In silco analysis utilizing the miRanda algorithm (35)
revealed several miRNAs with sites highly-complementary
to sequence in the Ccnb1 promoter. Of the five miRNAs
tested, three resulted in Ccnb1 induction. Additionally, we
previously reported two artificial dsRNAs with perfect
complementary to target sites located at 313 and 597
relative to the TSS that also activated Ccnb1 expression
(18). The ability to simply activate gene expression cannot
exclude the possibility that miRNAs/dsRNAs are func-
tioning through a canonical mechanism of gene silencing
and Ccnb1 induction is a consequence of downregulation
of other regulatory genes. If taken into consideration that
each functioning miRNA and dsRNA possesses a differ-
ent ‘seed’ sequence and targets non-overlapping regions,
the likelihood that each of the five duplexes induces Ccnb1
expression via suppression of common or different
upstream regulatory genes is potentially low. Their only
apparent similarity is that they all putatively target the
same gene promoter. ChIP analysis did reveal an enrich-
ment of Ago1 at the Ccnb1 promoter in vicinity close to
the putative miR-744 target site providing a direct linking
between the miRNA machinery and Ccnb1 promoter.
However, miRNAs failed to increase Ccnb1 promoter
activity in two reporter systems including a stably
integrated Ccnb1 promoter-GFP chimera and transiently
transfected luciferase reporter. We reason that promoter
environment plays a critical role in determining suscepti-
bility to gene activation mediated by miRNA. The cloned
promoter may not fully recapitulate context of the en-
dogenous environment. For instance, chromatin state, nu-
cleosome positioning and/or the presence of potential
regulatory non-coding transcript(s) may not be preserved
in the exogenous promoters. Models have implicated
overlapping antisense and/or promoter-derived cryptic
non-coding RNAs as target molecules for facilitating
RNAa and TGS (8,19,34,52,54,55). Such transcripts may
derive from sites outside the cloned promoter (e.g.
intragenic regions), which would be missing in the
reporter constructs.
We and others have previously shown that RNAa
mediated by synthetic dsRNA with perfect complemen-
tary to promoter sequence requires Ago2 for optimal
activity (33,34,56). However, gene knockdown and
overexpression experiments performed within this study
revealed Ago1 had greater impact on Ccnb1 expression
than Ago2 in context to miRNA-mediated Ccnb1 induc-
tion. ChIP analysis further indicated a selective enrich-
ment of only Ago1 protein at the Ccnb1 promoter.
Mescalchin et al. (57) has shown that Ago2 is primarily
involved in siRNA-mediated silencing pathways, while
Ago1 and other family members are primarily involved
in miRNA-mediated gene regulation. This segregation in
Ago protein function may also remain for mechanisms of
transcriptional regulation mediated by miRNA or perfect
dsRNA duplexes. In support, Ago1 has been reported to
be involved in miRNA-mediated TGS (31).
Prostate cancer progression is accompanied by
accumulating genetic alterations and CIN (58). As such,
features associated with karyotypic instability have been
identified in human prostate cancer cell lines (59,60).
Similarly, the mouse prostate TRAMP C1 cell line also
showed complex chromosomal abnormalities including
polyploidy, aneuploidy and structural rearrangements in-
dicative of chromosome/genome instability. It is note-
worthy to point out that Ccnb1 overexpression appeared
to enhance CIN in TRAMP C1 cells by promoting further
numerical and structural alterations including loss of
chromosomes (aneuploidy) and gain of additional
marker chromosomes. Interestingly, miR-744 and
miR-1186 also lead to similar chromosomal irregularities
suggesting miRNAs (i.e. miR-744) might impair chromo-
some segregation/maintenance machinery via activation
of Ccnb1 and render cancer cells more susceptible to cyto-
genetic alterations over time
It has been proposed that aneuploidy promotes tumori-
genesis (45). However, studies have also shown it may
function as a tumor suppressor in context to some cells
(61). We made an unexpected finding in that high passage
cells overexpressing miR-744 or miR-1186 possessed
reduced tumorigenicity in the TRAMP C1 xenograft
model. We speculate that the cytogenetic alteration result-
ing from Ccnb1 activation may have reduced viability and
hampered TRAMP C1 cell growth. Cancer cells possess a
dynamically balanced genome in order to maintain a
growth advantage. The cytogenetic alteration caused by
miRNA or Ccnb1 overexpression may disturb this
balance resulting in a loss of some tumorigenic features.
In summary, the present study provides evidence that
miRNA-mediated upregulation of gene expression func-
tions in physiological context of cancer within a mouse
model. We show activation of Ccnb1 by miRNA alters
the growth potential of TRAMP C1 cells both in vitro
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and in vivo. Short-term overexpression of miR-744 or
miR-1186 leads to enhanced cell proliferation, while
long-term expression alters chromosome composition
and negatively impacts tumor growth. We speculate that
endogenous miRNA may facilitate RNAa in cancer to
fine-tune gene expression and manipulate cancer cell
phenotype. Further study is needed to identify additional
examples and elucidate mechanism(s) by which miRNAs
directly activate gene expression and oncogenic pathways.
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